false
0002030763
0002030763
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 13, 2026
DATAMEDS
AI, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-42530 |
|
93-3264234 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
3000
Bayport Drive
Suite
950
Tampa,
FL 33607
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (844) 203-6092
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock, $0.0001 par
value per share |
|
MEDS |
|
The Nasdaq Capital Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02. Results of Operations and Financial Condition.
On
November 13, 2026, DataMEDS AI, Inc. (the “Company”) issued a press release announcing its financial results for the third
quarter ended September 30, 2026, and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form
8-K.
The
information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration
statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description
of Exhibit |
| 99.1 |
|
Press Release of DataMEDS AI, Inc. dated November 13, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the
Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date: November 13, 2026 |
DATAMEDS
AI, INC. |
| |
|
|
| |
By: |
/s/
Prashant Patel |
| |
|
Prashant Patel, President |
Exhibit 99.1
FOR
IMMEDIATE RELEASE
DataMEDS
AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides
Business Update
| ■ | Third
quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the second quarter of 2026,
primarily driven by growth in Corexa Pharmacy drug dispensing |
| ■ | Launch
of the Health Lives Here mobile app, partnered with the NFL Alumni Health marketing platform,
gives Corexa Pharmacy a unique customer acquisition channel to dispense FDA-approved GLP-1
medications and the medical food Forzet™ for the dietary management of muscle loss
associated with weight loss therapies |
| ■ | Exclusive
license to the REBOOT GLP-1 patient management platform and intellectual property creates
moat to scale customer acquisition and increase long-term customer value through patented,
AI-assisted patient management services |
| ■ | Corexa
Pharmacy launch of compounded peptides under FDA’s Enforcement Discretion Policy adds
an incremental revenue opportunity |
| ■ | MOU
with HMO to deploy the Health Lives Here mobile app to 25,000+ members provides institutional
customer to optimize PMPM model institutional customers |
| ■ | Acquisition
of Helomics cancer diagnostics laboratory, coupled with Humana Medicaid coverage for proprietary
ChemoFx® Assay, adds incremental proprietary revenue stream, in addition to traditional
lab services revenue, and opens cancer pharmaceuticals market for Corexa Pharmacy |
| ■ | Company
regains full compliance with Nasdaq listing standards |
Tampa,
Fla. – Monday, November 16, 2026 - DataMEDS AI, Inc. (“DataMEDS AI,” “DataMEDS” or the “Company”)
(NASDAQ: MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™
artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced financial results
for the third quarter ended September 30, 2026 and provided a business update.
“Corexa
Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the
steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense
prescriptions,” said Gerald Commissiong, Interim Co-CEO of DataMEDS. “Health Lives Here, backed by NFL Alumni Health, brings
patients to Corexa Pharmacy. The REBOOT license gives us patented, AI-assisted tools to keep GLP-1 patients engaged, proprietary Tollo
Health medical foods for muscle loss associated with weight loss therapies gives them unique tools to mitigate the drugs’ side
effects and Helomics adds diagnostic testing revenue streams. With our first HMO relationship and compounded peptides opening new channels,
and full Nasdaq compliance restored, we believe DataMEDS is well positioned for continued growth going forward.”
Business
Update
| ■ | Health
Lives Here and NFL Alumni Health. The Company launched the Health Lives Here mobile application,
partnered with the NFL Alumni Health marketing platform. The app gives Corexa Pharmacy a
unique customer acquisition channel to dispense FDA-approved GLP-1 medications and Forzet™,
a medical food for the dietary management of muscle loss associated with weight loss therapies. |
| ■ | REBOOT
GLP-1 license. In October 2026, DataMEDS obtained an exclusive license to the REBOOT
GLP-1 patient management platform and related intellectual property. The Company believes
these patented, AI-assisted patient management services create a moat that supports scaling
customer acquisition and increasing long-term customer value. |
| ■ | Compounded
peptides. In November 2026, Corexa Pharmacy launched compounded peptides under FDA’s
Enforcement Discretion Policy published in the Federal Register on October 30, 2026, adding
an incremental revenue opportunity. Compounded drugs are not FDA-approved and have not been
evaluated by FDA for safety or efficacy. |
| ■ | First
HMO relationship. In November 2026, the Company signed a non-binding memorandum of understanding
with a Florida-based HMO to deploy the Health Lives Here app to its 25,000+ members, providing
a platform to optimize user engagement for an institutional customer base. Definitive agreements
are expected in the fourth quarter of 2026. |
| ■ | Helomics.
In September 2026, DataMEDS acquired Helomics Corporation, a Pittsburgh-based CLIA-certified
cancer diagnostics laboratory. Humana’s South Carolina Medicaid coverage policy for
the proprietary ChemoFx® Assay, effective July 22, 2026, adds an incremental proprietary
revenue stream and opens the cancer pharmaceuticals market for Corexa Pharmacy. Additionally,
Helomics’ biobank of 70,000+ primary tumor biopsies creates drug discovery opportunities.
The Company is adding additional testing services to Helomics’ test menu to allow it
to support patient groups beyond cancer, especially GLP-1 patients. |
| ■ | Nasdaq
compliance. On October 19, 2026, the Company regained full compliance with Nasdaq listing
standards, including the net equity requirement. |
Profit
from Operations:
The
Company recorded a net operating profit of $10.535 million in the quarter ended September 30, 2026, compared with a net operating loss
of $34.318 million in the quarter ended September 30, 2025. The net profit in the third quarter of 2026 as compared with the net loss
in the third quarter of 2025 loss was largely due to the extinguishment of debt and outstanding liabilities related to litigation associated
with prior management and a reduction in expenses associated management compensation, as well as a reduction in general and administrative
expenses. Net profit per share in the quarter ended September 30, 2026 was $2.72 on 3.961 million weighted average shares outstanding,
compared to the quarter ended September 30, 2025, where the Company delivered a loss of $23.07 per share on 1.488 million weighted average
shares outstanding.
This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.
For
more information on DataMeds Ai, Inc., refer to www.datamedsai.com.
About
DataMEDS AI
DataMEDS
AI, Inc. (NASDAQ: MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology,
pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better
experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence
platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo
Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including
distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical
molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists
make chemotherapy treatment decisions. Learn more at https://datamedsai.com.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
are based on management’s current expectations and are not predictions of actual performance. Forward-looking statements include,
without limitation, statements regarding: the Company’s future revenue growth and financial results, including whether Corexa Pharmacy
dispensing revenue continues to grow; customer acquisition through the Health Lives Here app and the NFL Alumni Health marketing platform,
and related-party arrangements with Tollo Health, LLC; the scope, enforceability and competitive value of the REBOOT license and related
intellectual property; Corexa Pharmacy’s ability to compound and dispense peptides in compliance with FDA’s Enforcement Discretion
Policy and state pharmacy laws, and the possibility that the policy is changed or withdrawn; the non-binding nature of the HMO memorandum
of understanding and the possibility that definitive agreements are not executed on the expected timeline or at all; the integration
of Helomics and its ability to grow ChemoFx testing volumes and reimbursement; demand for GLP-1 medications and Forzet™ and the
regulatory status of medical foods; compliance with healthcare laws, including federal and state anti-kickback, beneficiary inducement
and privacy laws; the Company’s ability to maintain compliance with Nasdaq listing standards; and the Company’s liquidity,
capital resources and ability to fund operations. Actual results may differ materially from those expressed or implied in these forward-looking
statements due to a number of risks and uncertainties, including those described under “Risk Factors” in the Company’s
most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission, including its Quarterly Report
on Form 10-Q for the quarter ended September 30, 2026. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements,
except as required by law.
DataMEDS
AI Media Contact
James
Lambert, Vice President, Rubenstein Public Relations
212.805.3024
| jlambert@rubensteinpr.com
DataMEDS
AI Investor Contact
IR@datamedsai.com
PART
I—FINANCIAL INFORMATION
Item
1. Financial Statements.
DATAMEDS
AI, INC.
CONSOLIDATED
BALANCE SHEETS
(Unaudited)
| | |
September 30, 2026 | | |
December 31, 2025 | |
| | |
(Unaudited) | | |
| |
| ASSETS | |
| | | |
| | |
| Current assets: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 476,598 | | |
$ | 42,571 | |
| Accounts receivable, net | |
| 1,966,605 | | |
| 1,137,219 | |
| Inventories, net | |
| 1,440,296 | | |
| 1,639,426 | |
| Due from related parties | |
| 1,162,125 | | |
| - | |
| Prepaid and other current assets | |
| 174,411 | | |
| - | |
| Total current assets | |
| 5,220,035 | | |
| 2,819,216 | |
| Property, plant and equipment, net | |
| 323,305 | | |
| 229,376 | |
| Capitalized software | |
| 2,345,268 | | |
| 1,850,358 | |
| Operating lease, right-of-use-assets | |
| 1,590,240 | | |
| 966,893 | |
| Goodwill | |
| 15,787,176 | | |
| 14,193,923 | |
| Other intangible assets, net | |
| 13,249,358 | | |
| 10,314,675 | |
| Investment in SAFE | |
| 35,000 | | |
| - | |
| Deposits and other assets | |
| 183,486 | | |
| 85,008 | |
| Total assets | |
$ | 38,733,868 | | |
$ | 30,459,449 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 13,061,543 | | |
$ | 11,665,135 | |
| Accounts payable, related party | |
| 25,500 | | |
| 25,500 | |
| | |
| | | |
| | |
| Accrued expenses and other liabilities | |
| 3,647,245 | | |
| 6,407,722 | |
| Purchase consideration liability | |
| 1,885,700 | | |
| - | |
| Due to related parties | |
| - | | |
| 225,000 | |
| Convertible notes payable, net of debt discount | |
| 15,275,679 | | |
| - | |
| Current portion of debt obligations, net of debt discount | |
| 2,788,058 | | |
| 10,887,520 | |
| Operating lease liabilities- current portion | |
| 1,229,731 | | |
| 569,251 | |
| Total current liabilities | |
| 37,913,456 | | |
| 29,780,128 | |
| Note payable, net of discount | |
| 100,000 | | |
| 12,600,000 | |
| Operating lease liabilities | |
| 548,717 | | |
| 527,122 | |
| Total liabilities | |
$ | 38,562,173 | | |
$ | 42,907,250 | |
| | |
| | | |
| | |
| Commitments and contingencies (Note 15) | |
| | | |
| | |
| | |
| | | |
| | |
| Stockholders’ equity (deficit): | |
| | | |
| | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized, 4,740,862 and 4,730,148 shares issued and 2,836,484 and 2,026,150 shares outstanding as of September 30, 2026 and December 31, 2025, respectively | |
| 473 | | |
| 203 | |
| Additional paid-in capital | |
| 124,851,605 | | |
| 98,583,686 | |
| Accumulated deficit | |
| (126,547,748 | ) | |
| (111,031,690 | ) |
| Total DataMeds AI, Inc. stockholders’ equity (deficit) | |
| (1,695,670 | ) | |
| (12,447,801 | ) |
| Non-controlling interest | |
| 1,867,365 | | |
| - | |
| Total stockholders’ equity (deficit) | |
| 171,695 | | |
| (12,447,801 | ) |
| Total liabilities and stockholders’ equity (deficit) | |
$ | 38,733,868 | | |
$ | 30,459,449 | |
DATAMEDS
AI, INC.
CONSOLIDATED
STATEMENTS OF OPERATIONS
(Unaudited)
| | |
Three Months Ended | | |
Nine Months Ended | |
| | |
September 30, | | |
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Net revenues | |
$ | 2,668,980 | | |
$ | 3,012,904 | | |
$ | 6,008,403 | | |
$ | 21,667,212 | |
| Cost of net revenues | |
| 2,237,100 | | |
| 2,781,892 | | |
| 5,224,098 | | |
| 20,237,807 | |
| Gross profit (loss) | |
| 431,880 | | |
| 231,012 | | |
| 784,305 | | |
| 1,429,405 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| General and administrative | |
| 3,343,627 | | |
| 30,172,800 | | |
| 15,269,233 | | |
| 66,205,669 | |
| Sales and marketing | |
| 105,788 | | |
| 803,747 | | |
| 1,179,778 | | |
| 1,212,347 | |
| Depreciation and amortization | |
| 356,421 | | |
| 802,794 | | |
| 1,069,842 | | |
| 2,408,462 | |
| Total operating expenses | |
| 3,805,836 | | |
| 31,779,341 | | |
| 17,518,853 | | |
| 69,826,478 | |
| | |
| | | |
| | | |
| | | |
| | |
| Loss from operations | |
| (3,373,956 | ) | |
| (31,548,329 | ) | |
| (16,734,548 | ) | |
| (68,397,073 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Other income (expense): | |
| | | |
| | | |
| | | |
| - | |
| Interest expense, net | |
| (2,252,401 | ) | |
| (1,425,307 | ) | |
| (5,886,320 | ) | |
| (3,703,837 | ) |
| Loss on extinguishment of vendor obligation | |
| (3,605,978 | ) | |
| - | | |
| (3,666,098 | ) | |
| - | |
| Gain (loss) on extinguishment of debt | |
| 19,064,881 | | |
| (1,353,663 | ) | |
| 10,183,187 | | |
| (1,353,663 | ) |
| Loss on contract termination fee | |
| - | | |
| - | | |
| (766,394 | ) | |
| - | |
| Settlement fees | |
| - | | |
| - | | |
| (13,000 | ) | |
| - | |
| Other income | |
| 703,014 | | |
| 9,095 | | |
| 1,312,911 | | |
| 33,002 | |
| Total other income (expense), net | |
| 13,909,516 | | |
| (2,769,875 | ) | |
| 1,164,286 | | |
| (5,024,498 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) before income taxes | |
| 10,535,560 | | |
| (34,318,204 | ) | |
| (15,570,262 | ) | |
| (73,421,571 | ) |
| Provision for income taxes | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) | |
$ | 10,535,560 | | |
$ | (34,318,204 | ) | |
$ | (15,570,262 | ) | |
$ | (73,421,571 | ) |
| Net loss attributable to non-controlling interest | |
| (54,204 | ) | |
| - | | |
| (54,204 | ) | |
| - | |
| Net income (loss) attributable to DataMeds AI | |
$ | 10,589,764 | | |
$ | (34,318,204 | ) | |
$ | (15,516,058 | ) | |
$ | (73,421,571 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average common shares outstanding - basic and diluted | |
| | | |
| | | |
| | | |
| | |
| Basic | |
| 3,214,663 | | |
| 1,487,588 | | |
| 2,636,382 | | |
| 1,249,164 | |
| Diluted | |
| 3,961,210 | | |
| 1,487,588 | | |
| 2,636,382 | | |
| 1,249,164 | |
| Net loss per common share - basic and diluted | |
| | | |
| | | |
| | | |
| | |
| Basic | |
$ | 3.29 | | |
$ | (23.07 | ) | |
$ | (5.89 | ) | |
$ | (58.78 | ) |
| Diluted | |
$ | 2.72 | | |
$ | (23.07 | ) | |
$ | (5.89 | ) | |
$ | (58.78 | ) |
###
